36th week of 2012 patent applcation highlights part 37 |
Patent application number | Title | Published |
20120225792 | Gene Expression Biomarkers in PAP Test Material for Assessing HPV Presence and Persistence - In accordance with certain embodiments of the present disclosure, a method for the diagnosis of persistent HR-HPV in an individual is provided. An expression level of at least one biomarker in a biological sample is determined. The expression level of the at least one biomarker is compared to an expression level of corresponding biomarker(s) in a comparative sample, wherein the comparative sample contains the at least one biomarker in a level indicative of persistent HR-HPV. Persistent HR-HPV infection is predicted in the individual based upon the comparison of the expression level of the at least one biomarker between the comparative sample and the biological sample. | 2012-09-06 |
20120225793 | METHODS FOR IDENTIFYING, DIAGNOSING, AND PREDICTING SURVIVAL OF LYMPHOMAS - Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject. | 2012-09-06 |
20120225794 | Antibodies Specific to Heterodimers of Bcl-2 Family and Uses Thereof - Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient. | 2012-09-06 |
20120225795 | PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer. | 2012-09-06 |
20120225796 | TOOL FOR DIAGNOSIS AND PROGNOSIS OF MATURE B-CELL NEOPLASMS - The present invention provides a microarray useful as a tool in the diagnosis and/or prognosis of certain types of cancers, particularly mature B-cell neoplasms. The microarray can include a plurality of genomic regions represented thereon, the genomic regions corresponding to regions wherein alterations, such as copy number alterations, at such locations correlate to specific, identifiable cancers, particularly mature B-cell neoplasms. The invention further provides methods of diagnosing and providing prognosis certain types of cancer, particularly mature B-cell neoplasms. The methods can comprise contacting a sample to a microarray according to the invention, allowing any genetic material in the sample to hybridize to the genomic regions on the microarray, analyzing the hybridizations, and correlating the hybridizations to certain cancer types, particularly mature B-cell neoplasms. | 2012-09-06 |
20120225797 | MULTIPLEXED SCREENING OF ENZYME ACTIVITIES USING NANOSTRUCTURE-INITIATOR MASS SPECTROMETRY - Disclosed herein are methods, compositions and systems for analyzing and detecting enzyme activity. For examples, methods, compositions and systems for parallel detection and analysis of enzymatic activities of enzymes in complex biological mixtures are provided. | 2012-09-06 |
20120225798 | METHOD FOR NON-INVASIVE PRENATAL DIAGNOSIS - The present invention is directed to methods of detecting nucleic acids in a biological sample. The method is based on a novel combination of a base extension reaction, which provides excellent analytical specificity, and a mass spectrometric analysis, which provides excellent specificity. The method can be used, for example, for diagnostic, prognostic and treatment purposes. The method allows accurate detection of nucleic acids that are present in very small amounts in a biological sample. For example, the method of the present invention is preferably used to detect fetal nucleic acid in a maternal blood sample; circulating tumor-specific nucleic acids in a blood, urine or stool sample; and donor-specific nucleic acids in transplant recipients. In another embodiment, one can detect viral, bacterial, fungal, or other foreign nucleic acids in a biological sample. | 2012-09-06 |
20120225799 | Systems and Methods For Forming High Performance Compressible Objects - The present systems and methods utilize a polyamic acid solution as a precursor to form a polyimide bead having desired properties. The polyamic acid solution may be formed into a polyamic acid droplet. The polyamic acid droplet is then processed to form a polyamic acid bead, such as by extraction of solvent to concentrate the polyamic acid or by partial chemical imidization of the polyamic acid. The polyamic acid bead is then better able to retain its shape during subsequent processing steps, such as drying and pressurizing, before final thermal imidization. | 2012-09-06 |
20120225800 | HYDRAULIC FRACTURE COMPOSITION AND METHOD - A method for improving hydraulic fracturing creates coated proppants containing one or more chemical constituents bonded to a substrate and introduced into the fracturing fluid itself. The substrate that eventually acts as a proppant may be sand, ceramic, resin coated sand, and other materials. Typically, the materials that are coated as powders adhered to the substrate may include friction reducers, biosides, oxygen scavengers, clay stabilizers, scale inhibitors, gelling agents, or the like. By adhering solid materials to a substrate | 2012-09-06 |
20120225801 | ELECTROCHEMICAL ENHANCEMENT OF DETERGENT ALKALINITY - A device for in-situ production of caustic and increasing alkalinity of a detergent and methods for increasing alkalinity of a detergent are disclosed. In particular, in situ electrochemical conversion of bicarbonate, sesquicarbonate or carbonate sources into caustic provides a safe means for increasing alkalinity of a detergent for a variety of cleaning applications. The invention further discloses methods for cleaning using the electrochemically enhanced detergent according to the invention. | 2012-09-06 |
20120225802 | DISHWASHING METHOD - The present invention relates to a method of manually cleaning dishware using a liquid hand dishwashing detergent composition comprising an anionic surfactant and a cationic polymer having a MW below or equal to 2,100,000; and a charge density above or equal to 0.45 meq/g, wherein such composition will have a coacervation index upon dilution of at least 2.5%; to provide skin care. | 2012-09-06 |
20120225803 | DYE POLYMERS - The present invention relates to polymeric shading dye and their use in laundry applications. The polymers are polyethylene imines and the dyes are reactive dyes. | 2012-09-06 |
20120225804 | MICROFIBROUS CELLULOSE AND ALKALINE EARTH METAL ION STRUCTURED SURFACTANT COMPOSITION - An aqueous composition comprising at least one surfactant; a suspending agent comprising micro fibrous cellulose; 10 to 600 ppm of an alkaline earth metal ion, and water. The composition can be used to structure surfactant systems to suspend material in the composition. | 2012-09-06 |
20120225805 | FAST DRYING AND FAST DRAINING RINSE AID - The present invention is directed to rinse aid compositions and methods for making and using the rinse aid compositions. The compositions of the invention include a sheeting agent, a defoaming agent, and an association disruption agent. The rinse aid compositions of the present invention result in a faster draining/drying time on most substrates compared to conventional rinse aids. The rinse aid compositions of the present invention are especially suitable for use on plastic substrates. | 2012-09-06 |
20120225806 | COMPOSITIONS AND METHOD OF DELIVERY - A method of delivering a material to a person comprising applying an anhydrous composition to a person, wherein the anhydrous composition comprises a base and metal organic framework formed from a recyclable porous material with the material adsorbed into the metal organic framework, and the recyclable porous material has a structure that breaks down when contacted with water to release the material. An anhydrous composition comprising a base and a metal organic framework formed from a recyclable porous material with the material adsorbed into the metal organic framework, wherein the recyclable porous material has a structure that breaks down when contacted with water to release the material. | 2012-09-06 |
20120225807 | BACTERIAL MEMBRANE PROTEIN SECRETION - Improved bacterial secretion signals derived from pelB and ompA are provided. The improved variants enhance bacterial membrane secretion are thus useful for production of proteins secreted from bacteria including proteins displayed on filamentous phage particles, and, in particular, proteins requiring oxidative formation of covalent bonds, such as disulfide bonds within or between polypeptide chains in order to form a correctly folded and functional protein structure. Described herein are methods for the multivalent display of complex dimeric proteins on the surface of a bacteriophage particle and combinatorial synthetic libraries of such proteins displayed as a fusion polypeptide with filamentous phage pIX coat protein. Heterodimeric or more complex interchain bonded structures may also be displayed using the method of the invention. | 2012-09-06 |
20120225808 | Pharmaceutical Composition for Preventing / Treating TRPV1 Activity-Related and Inflammation-Related Diseases or Conditions Containing Maillard Peptide Separated from Well-Aged Traditional Soy Sauce as Active Ingredient - The present invention relates to a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide according to the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and thus functions as a TRPV1 activity modulator. Therefore, the present Maillard peptide can be used as a pharmaceutical composition for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic/allergic/inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc. In addition, the Maillard peptide of the present invention can inhibit COX-2 activity, and therefore can be effectively used as a pharmaceutical composition for preventing or treating inflammation-related diseases or conditions such as rheumatic fever, influenza, cold, throat pain, headaches, toothaches, sprains, neuralgia, synovitis, rheumatoid arthritis, degenerative arthropathies, gout, ankylosing spondylitis, psoriasis, dermatitis, etc. | 2012-09-06 |
20120225809 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION - The present invention relates to polyamide compositions and therapies for treating cells and subjects infected with papilloma virus. | 2012-09-06 |
20120225810 | PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES - The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation. | 2012-09-06 |
20120225811 | INSULIN ANALOGUES - A dicarba analogue of insulin comprising an A-chain and a B-chain or fragments, salts, solvates, derivatives, isomers or tautomers of the A-chain, the B-chain or both, provided that the dicarba analogue is not [A7,B7-(2,7-diaminosuberoyl]-des-(B26-B30)-insulin B25-amide. | 2012-09-06 |
20120225812 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF - The present invention provides substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. | 2012-09-06 |
20120225813 | COMPOSITIONS, METHODS AND USES FOR TREATMENT OF TYPE 1 DIABETES - Embodiments herein concern compositions and methods for treating diabetes in a subject. | 2012-09-06 |
20120225814 | HYDROGEL-BASED VASCULAR LINEAGE CELL GROWTH MEDIA AND USES THEREOF - A medium for growing vascular lineage cells is described. The vascular lineage cell growth medium includes an oligosaccharide-based hydrogel and a growth factor that promotes vascularization by vascular lineage cells. | 2012-09-06 |
20120225815 | Novel Cellular Factor-Containing Solution Compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 2012-09-06 |
20120225816 | Pharmaceutical Compositions of Melanocortin Receptor Ligands - The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH | 2012-09-06 |
20120225817 | THERAPEUTIC AGENT FOR GASTROINTESTINAL DISEASE - The present invention provides a therapeutic agent and a prophylactic agent for a gastrointestinal disease. A peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof promotes wound healing in a gastrointestinal mucosal tissue, and is therefore useful as a therapeutic agent or a prophylactic agent for a gastrointestinal disease. Further, when (a) a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof and (b) a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH | 2012-09-06 |
20120225818 | PLASMA PROTEIN EFFECTIVE FOR SUPPRESSING COUGH - The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. | 2012-09-06 |
20120225819 | STABLE FORMULATION OF FACTOR VIII - The invention relates inter alia to a composition which is storage-stable at 25° C. for a minimum of 18 weeks comprising a therapeutically effective amount of Factor VIII and an aqueous medium having a Factor VIII potency after 18 weeks of storage at 25° C. of at least 90% of the Factor VIII potency of a Control Composition. | 2012-09-06 |
20120225820 | PEPTIDES ASSOCIATED WITH HLA-DR MHC CLASS II MOLECULE AND INVOLVED IN RHEUMATOID ARTHRITIS - Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with rheumatoid arthritis. These novel peptides provide the basis for new methods of diagnosis and treatment of rheumatoid arthritis. | 2012-09-06 |
20120225821 | COMPOSITION FOR PREVENTING OR TREATING A SPINAL CORD INJURY - The present invention relates to a novel use of substance P. The substance P of the present invention exhibits effects of decreasing microglia activity, decreasing proinflammatory cytokines, inhibiting apoptosis, etc. The substance P of the present invention effectively treats degenerative central nervous system diseases or disorders such as a spinal cord injury caused by a traumatic injury (flexion injury, vertical compression injury, hyperextension injury, flexion-rotation injury) and by a non-traumatic injury (vascular dysfunction, arthritis, or degenerative arthritis), Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, depressive disorder, epilepsy, etc. | 2012-09-06 |
20120225822 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS - Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder. | 2012-09-06 |
20120225823 | Allosteric Modulation of the Dopamine Transporter Protein for the Treatment of HIV-1 Induced Neurologic Dysfunction - A method for increasing dopaminergic neurotransmission in a mammal in need of such treatment is provided. The method comprises disrupting Tat-DAT binding in the mammal. | 2012-09-06 |
20120225824 | MULLERIAN INHIBITING SUBSTANCE (MIS) ANALOGUES - Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositions comprising such compositions and methods of using such compositions, for example in the treatment of conditions associated with uncontrolled growth of a tissue derived from a Mullerian duct, such as the condition endometriosis. | 2012-09-06 |
20120225825 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 2012-09-06 |
20120225826 | Transporters Comprising Spaced Arginine Moieties - The present invention provides compositions and methods for enhancing transport of biologically active compounds across biological membranes and across and into animal epithelial or endothelial tissues. The composition includes a biologically active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ) | 2012-09-06 |
20120225827 | SILICONE-BASED OPHTHALMIC FORMULATIONS - Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases. | 2012-09-06 |
20120225828 | Melanocortin-1 Receptor-Specific Cyclic Peptides - Melanocortin receptor-specific cyclic peptides of the formula | 2012-09-06 |
20120225829 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 2012-09-06 |
20120225830 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 2012-09-06 |
20120225831 | Melanocortin-1 Receptor-Specific Linear Peptides - Melanocortin receptor-specific linear peptides of the formula | 2012-09-06 |
20120225832 | Amphiphilic Compositions and Methods for Preparing and Using Same - The invention relates to amphiphilic C-glycoside derivatives, to methods of using them and to processes for synthesizing them. Specifically, the invention relates to novel cyclic and linear enone-glycolipids and cyclic ketone-glycolipids. | 2012-09-06 |
20120225833 | COMPOSITION FOR TREATING MENTAL HEALTH DISORDERS - A composition of three compounds each selected from a selective re-uptake inhibitor of serotonin, a monoamine oxidase inhibitor, and a phosphodiesterase inhibitor, such that all three compounds are different and are naturally occurring. | 2012-09-06 |
20120225834 | OCULAR IONTOPHORESIS OF CHARGED MICELLES CONTAINING BIOACTIVE AGENTS - This invention is related to pharmaceutical compositions consisting of charged micelles containing bioactive agents. The invention is also related to the methods of delivery of charged micelles to the eye of a mammal by iontophoresis. | 2012-09-06 |
20120225835 | ANTIBIOTIC FORMULATIONS, UNIT DOSES, KITS, AND METHODS - An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods. | 2012-09-06 |
20120225836 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF - Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly. | 2012-09-06 |
20120225837 | MEDICINAL AGENT FOR DISEASE ASSOCIATED WITH EPSTEIN-BARR VIRUS, AND METHOD FOR SCREENING OF THE MEDICINAL AGENT - 1-(2-Fluoro-4-thio-β-D-arabinofuranosyl)-5-methyluracil exhibits an anti-EB virus activity, and is therefore effective as a prophylactic or therapeutic agent for a disease associated with an EB virus. Each of a plasmid capable of expressing EB virus-TK and a plasmid capable of expressing human-TK is introduced into a TK-defect cell, thereby producing two types of cells respectively having the plasmids introduced therein. By using the two types of cells, it is possible to screen a medicinal agent which has cytotoxicity against the cell having the plasmid capable of expressing EB virus-TK introduced therein but has no toxicity against the cell having the plasmid capable of expressing human-TK introduced therein. In this manner, it becomes possible to screen a medicinal agent which specifically exhibits an anti-EB virus activity. | 2012-09-06 |
20120225838 | ANTI-TUMOR EFFECT POTENTIATOR - There is provided an agent for potentiating the effects of an anti-tumor agent. | 2012-09-06 |
20120225839 | Phosphoramidate Derivatives of Nucleosides - Compounds of formula I: | 2012-09-06 |
20120225840 | HYDROXYTYROSOL COMBINATIONS FOR ENHANCING MITOCHONDRIAL FUNCTION AND ENERGY PRODUCTION - Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue. | 2012-09-06 |
20120225841 | Methods of Making and Using a Ruminant Gas Reduction Composition - A method comprising administering an oligosaccharide composition to an organism having a gastrointestinal system to affect the production of GHG produced by the organism allowing for a reduction of the GHG produced by the organism while optimizing the health, feed intake, and protein synthesis of the organism so that management of the organism may realize the synergistic effects of maximizing both typical organism commodity-type concerns (e.g., size and production metrics) and atypical organism commodity-type concerns (e.g., carbon credit trading/monetization). A gas-reducing composition comprising soluble extractable material from a lignocellulosic source. A method of producing a composition, comprising providing a lignocellulosic source; extracting soluble materials from the lignocellulosic source to produce soluble extractable material; and processing the soluble extractable material to yield a gas-reducing composition, wherein the gas-reducing composition comprises hemicellulose and exhibits gas-reducing activity. | 2012-09-06 |
20120225842 | HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE - The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional constituent selected from the group consisting of vitamin B, C and vitamin E, wherein the formulation exhibits greater stability than an HA gel formulation without the additional constituent. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well. | 2012-09-06 |
20120225843 | Use of Sulfated Glycosaminoglycans for Establishing Effective Labor in Women - A method of treating protracted labor in a pregnant woman comprises administering to a pregnant woman an effective amount of a depolymerised low molecular weight heparin treated with periodate to eradicate antithrombin III binding affinities, thereby exhibiting an anticoagulant activity of 10 BP units/mg or less and an average molecular weight not higher than 10000 Da to prime or curatively treat the cervix and myometrium and for treatment of slow progress of labor. A method for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in a pregnant woman comprises administering to a pregnant woman an effective amount of a depolymerised low molecular weight heparin as described to prophylactically prime or curatively treat the cervix and myometrium and for establishing effective labor in the pregnant woman. | 2012-09-06 |
20120225844 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2012-09-06 |
20120225845 | COMPOUNDS FOR DISEASES AND DISORDERS - The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH | 2012-09-06 |
20120225846 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK - Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus. | 2012-09-06 |
20120225847 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE - The present application discloses novel squaric acid derivatives of the formula A: from —C(═O)—, —S(═O) | 2012-09-06 |
20120225848 | Antagonists of GABA-B Receptors to Enhance Neuronal Function, Learning and Memory - Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a GABAB antagonist, or a blocker of Kir3.2 potassium channels, is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications. | 2012-09-06 |
20120225849 | 2-Methoxyestradiol (2-ME2) Prodrug with Enhanced Bioavailability for Prophylaxis or Treatment of Cancerous or Non-Cancerous Condition - A prodrug of 2-methoxyestradiol (2-ME | 2012-09-06 |
20120225850 | Steroidal antitubercular compounds - A steroidal compound n-hexyl-p-stigmasteryloxy-benzoate is reported as a novel potent antitubercular drug. | 2012-09-06 |
20120225851 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES - The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia′, Ib′, Ic′, or II′ (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds or Formula Ia, Ib, Ic, or II in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula Ia′, Ib′, Ic′, or II′. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. | 2012-09-06 |
20120225852 | USE OF STEROID COMPOUNDS - This invention pertains to the use of steroid compounds including spirosteroid analogues in treating, preventing or ameliorating the symptoms of inflammatory conditions. The steroid compounds are useful for treating a range of inflammatory conditions, including, but not limited to asthma, lung inflammation, retinal inflammatory conditions, autoimmune diseases such as rheumatoid arthritis, diabetes type I, systemic lupus erythematosus, ulcerative colitis and inflammatory bowel diseases and myopathies, as well as multiple sclerosis. The active compounds are represented by Formula I: | 2012-09-06 |
20120225853 | HORMONE REPLACEMENT THERAPY AND DEPRESSION - The treatment and/or prevention of depression by the co-administration of an estrogen with the progestin dienogest for HRT and/or contraception. | 2012-09-06 |
20120225854 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, | 2012-09-06 |
20120225855 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS - A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R | 2012-09-06 |
20120225856 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 2012-09-06 |
20120225857 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE - Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders. | 2012-09-06 |
20120225858 | 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS - The present invention relates to 1,4 Thiazepines/Sulfones of formula I | 2012-09-06 |
20120225859 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS - Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases. | 2012-09-06 |
20120225860 | METHOD FOR ADMINISTRATION OF A GAMMA SECRETASE INHIBITOR - There are provided a new dosage regimens for the gamma secretase inhibitor 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide which maximizes anti-tumor activity while maintaining acceptable toxicity levels. | 2012-09-06 |
20120225861 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling - Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R. | 2012-09-06 |
20120225862 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE - Provided are certain heteroaryl benzamides, compositions, and methods of their manufacture and use. | 2012-09-06 |
20120225863 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK - Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus. | 2012-09-06 |
20120225864 | Methods and Compositions for Modulating Tau Levels - Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided. | 2012-09-06 |
20120225865 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES - The present invention is concerned with arylcyclohexylethers of dihydro-tetraazabenzoazulenes, i.e. arylcyclohexylethers of 5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula I | 2012-09-06 |
20120225866 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION - The present invention provides a novel diazepine compound that blocks the I | 2012-09-06 |
20120225867 | ANDROGEN RECEPTOR MODULATING COMPOUNDS - The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof. | 2012-09-06 |
20120225868 | NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS - The present invention is concerned with novel dual modulators of the 5-HT | 2012-09-06 |
20120225869 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1). | 2012-09-06 |
20120225870 | METHODS FOR TREATING CANCER RESISTANT TO ERBB THERAPEUTICS - Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell. | 2012-09-06 |
20120225871 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY - Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression. | 2012-09-06 |
20120225872 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES - A method of preparing a compound of formula (I), | 2012-09-06 |
20120225873 | COMPOUNDS FOR ALZHEIMER'S DISEASE - The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH | 2012-09-06 |
20120225874 | BICYCLIC DERIVATIVES AS CETP INHIBITORS - The present invention relates to novel compounds of formula (I) | 2012-09-06 |
20120225875 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS - Novel hetarylaminoquinoline derivatives of formula (I) | 2012-09-06 |
20120225876 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE - Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R | 2012-09-06 |
20120225877 | SUBSTITUTED 1, 4-DIOXA-8-AZASPIRO[4,5]DECANES USEFUL AS FUNGICIDES AND A PROCESS FOR THE PREPARATION THEREOF - This invention relates provides novel substituted 1,4-dioxa-8-azaspiro[4,5]decane of general formula (1), wherein R1 is selected from phenethyl, 4,6-dimethoxypyrimidin-2-yl and (2-chloro-5-thiazolyl)methyl and R2 is selected from the group consisting of hydroxy, 4-bromo-2-chlorophenoxy, morpholin-4-yl, (2-chloro-5-thiazolyl)methyloxy, benzyloxy, phenylsulfanyl, benzotriazol-1-yl and 5-chloro-2-fluoroanilino. The present invention also relates to a process for the preparation of novel substituted 1,4-dioxa-8-azaspiro[4,5]decanes of general formula (1). The novel substituted 1,4-dioxa-8-azaspiro[4,5]decane of general formula (1) has fungicidal activity. | 2012-09-06 |
20120225878 | COMPOUNDS - The present invention relates to substituted triazole compounds of the formula (I): | 2012-09-06 |
20120225879 | SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES - The present invention is based on the use of a broad family of 5-imino-1,2,4-thiadiazoles as potential new drugs for the treatment of diseases in which PDE7 inhibition is important, specially inflammatory diseases, autoimmune and neurodegenerative disorders. On the other hand, compounds of the 5-imino-1,2,4-thiadiazole family are here described, as well as their synthetic procedures, and they may have great application as drug or drug candidates. | 2012-09-06 |
20120225880 | PYRAZOLE COMPOUNDS AND THIAZOLE COMPOUNDS AS PROTEIN KINASES INHIBITORS - A compound of formula (I): | 2012-09-06 |
20120225881 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYRDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS - The compounds shown by the structural formulas below have analgesic effect and are used in compositions and methods for treating mammal in need of such treatment. | 2012-09-06 |
20120225882 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS - The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition. | 2012-09-06 |
20120225883 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formulas (I), (VII) and (XI): | 2012-09-06 |
20120225884 | BRIDGED PIPERIDINE DERIVATIVES - The present invention relates to compounds of formula I | 2012-09-06 |
20120225885 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to novel imidazole compounds, pharmaceutical compositions comprising the imidazole compounds and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: | 2012-09-06 |
20120225886 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS - The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. | 2012-09-06 |
20120225887 | Glucokinase Activators - Compounds are provided for use with glucokinase that comprise the formula: | 2012-09-06 |
20120225888 | Inhibitors of Human Immunodeficiency Virus Replication - The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. | 2012-09-06 |
20120225889 | USE OF MACROCYCLIC LACTONE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention provides use of the compounds represented by formula (1): wherein, R | 2012-09-06 |
20120225890 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND PARKINSON'S DISEASE - Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment. | 2012-09-06 |
20120225891 | AMIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS INSECTICIDE - A compound represented by Formula (1): | 2012-09-06 |